GBIO vs AKRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AKRO Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GBIO counters with relative strength in Valuation. Fundamentally, GBIO trades at 7.9x Forward P/E with -2020.0% operating margin (-78.9% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GBIO | AKRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $38.7M | $4.5B | Larger Scale | AKRO |
| Trailing P/E Ratio Valuation | 7.9x | N/M | Lower Multiple | GBIO |
| Forward P/E Ratio Valuation | 7.9x | N/M | Lower Multiple | GBIO |
| Revenue Growth (YoY) Growth | -78.9% | +0.0% | Higher Growth | AKRO |
| Operating Margin (TTM) Profitability | -2020.0% | 0.0% | Higher Margin | AKRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -80.8% | -34.5% | Higher ROE | AKRO |
| 52-Week Range Position Momentum | 62% ($0โ$8) | 90% ($21โ$58) | Stronger Trend | AKRO |
| Beta / 30D Volatility Risk Regime | 0.80ฮฒ ยท 26% Vol | 0.90ฮฒ ยท 2% Vol | Lower Realized Risk | AKRO |
| Unified Institutional Score Composite Signal | 58.8 / 100 (HOLD) | 60.0 / 100 (BUY) | Higher Composite | AKRO |